Furthermore, CHI3L1 may serve as a non-invasive staging marker for liver fibrosis caused by HBV, HCV, and nonalcoholic fatty liver disease or as a tool to predict the response to antiviral therapy in chronic HBV patients [78]. This evidence concerns the gene CHI3L1 and Hepatic fibrosis.